Akura Medical Closes Series B Financing for Mechanical Thrombectomy Platform

October 3, 2023—Akura Medical, a Shifamed portfolio company focused on treating venous thromboembolism, announced the closing of its $35 million Series B financing.

According to the company, the funds will be used to apply for FDA 510(k) clearance for the Akura mechanical thrombectomy platform, support clinical trials for additional indications, and scale manufacturing capabilities. The platform is in the research and development phase and is not FDA cleared, CE Mark approved, or approved for sale worldwide.

The financing was led by The Capital Partnership and Cormorant Asset Management, with significant participation from the PA MedTech VC Fund, AMED Ventures, Lilly Asia Ventures, Unorthodox Ventures, and Shifamed angel investors, advised the company.

The Akura mechanical thrombectomy platform is designed to be an easy-to-use, smaller bore system. The low-profile, steerable sheath allows physicians to bring the tip of the catheter directly to the proximal end of the clot without having to cross the clot.

The platform’s integrated aspiration and maceration technology, incorporating intersecting jets, aims to enable efficient removal of mixed morphology clots. Additionally, pressure sensors provide real-time hemodynamic data, reducing the guesswork around case progress, stated Akura Medical.